Podcasts about iii iv

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company's investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy's potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

„Nuo pat tos akimirkos, kai popiežius Pranciškus pasirinko precedento neturintį - ir bauginantį - vardą, jį imta lyginti su šv. Pranciškumi Asyžiečiu, kuris, kaip ir jo bendražygis vienuolijos steigėjas šv. Benediktas, be savo liturginės iškilmės spalio 4-ąją viena diena anksčiau mini savo „transitus“, arba perėjimą iš šio gyvenimo į kitą. Asyžiaus neturtėlio atveju tai ypač dera, prisimenant jo meilę „Sesei Mirčiai“ ir Kristaus kryžiui, kurią liudija jo stigmos. Pastarosiomis savaitėmis popiežius Pranciškus patyrė kai ką panašaus į tokį „transitus“. Nors jis tebėra gyvas ir jo būklė iš lėto taisosi, jo amžius ir tolydžio silpstanti sveikata tikrai pranašauja paskutinį jo pontifikato etapą". Plačiau - vedamojo skiltyje.Vilniaus knygų mugės metu buvo pristatyta dar viena į lietuvių kalbą išversta anglų rašytojo Evely'on Waugh knyga – jo romanas „Elena“, pasakojantis apie III-IV amžių sandūroje gyvenusią imperatorienę Eleną, kurią Katalikų Bažnyčia gerbia kaip šventąją tikrojo Kristaus kryžiaus atradėją. Apie kūrinį pasakoja jo vertėjas Augminas Petronis.Spaudos apžvalga: amerikiečių rašytojos katalikės Flannery O'Connor 100-ųjų gimimo metinių sukaktis (parengė Rosita Garškaitė-Antonowicz.„Krikščioniškosios minties puslapis“: „Pašaukti į sąžinę“.„Tėvo Antano pasakojimai“: kun. Antanas Saulaitis SJ apie Atgailos sakramentą.„Laisvas stilius“: Giedrės Kazlauskaitės radijo apybraiža „Sacrum ir profanum Pievėnuose“.Redaktoriai Rūta Tumėnaitė ir Julius Sasnauskas.

Chuck Quinn III and Chuck Quinn IV, a father and son duo, are performing together in Deerfield Theater's upcoming production of Our Town. They share their unique experiences of working together on stage, the deep bond it forms, and how their real-life relationship influences their portrayal of their characters in the play, and vice versa. They reflect on the significance of the play's themes of cherishing everyday moments, especially poignant after the pandemic. Both Chucks describe their journey in theater and offer insights into how performing arts have impacted their lives. They encourage audiences to see Our Town, highlighting its timeless message and the joy of live theater.Theater D Presents: Our TownPerformances at Caruso Auditorium, 1801 Montgomery Rd., Deerfield on:* Fridays, March 28, 4, and 11 at 7:30pm* Saturdays, March 29, April 5 and 12 at 7:30pm* Sundays, March 30, April 6 and 13 at 2:00pmDeerfield TheaterPurchase Tickets This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit deerfieldtheater.substack.com

This week on Movies, Comics and TeleVision, Corey and Marc discuss:00:44 - The Russo's seem pumped to be back with Marvel. Does their recent string of badly reviewed movies hurt?20:39 - A new podcast from DC, and Marc talks about John Cena (sorry)37:04 - Television Round Up47:44 - ‘DAREDEVIL: BORN AGAIN' Episodes III and IVHave a question for the fellas? Follow us on social media @MCTVPodcast, or visit MCTVPodcast.comMusic provided by WHALE AND THE WOLF. Check out their music on Apple and Spotify.

www.fed965.comCollaborations, Meetings, Sessions — babyblueviperbusiness@gmail.com .X — Chill0006LinkedIn — Federico Blanco Sánchez-Llanos This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.fed965.com/subscribe

On the completion of the podcast series, Portraits of Clongowes, Dec Ryan reviews the episodes with Rossa McDermott, informally bringing closure on the 100 episodes in Series I, II, III & IV recorded over the past eighteen months.The latest podcast series were made possible by the kind support of Jigsaw Youth Mental Health, Hannon Travel. Liz O'Kane Buying Agent, and GoFundMe. The generosity of spirit, the positive feedback and the sponsors support has been more than generous.Other individuals silently donated to the project along the way , offered encouragement and ensured the series continued so that most people who wanted had a chance to share their memories.The Wrap Questions …. Tune in.

Donate to support GG Podcast: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ko-fi.com/jside⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Join the GG Discord! : ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://discord.gg/gsHTFJWewe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Genshin Guys Twitter - @GenshinGuysPod  JSide Twitch - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://twitch.tv/jside⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ JSide Twitter - @jsidegaming  Kahi Twitter & Youtube - @Kahiyao Episode 089 - In this episode, we can talk about our impressions of Natlan so far as well as the next two acts of the Archon Quest~! New community question:  Who did you bring to the fight? Send us your answer to the community question through either Discord or in the Spotify comments! BGM by 3AMAudio from Pixabay Original music by Yu-peng Chen and HoYo Mix. Voicelines by Hoyoverse.

El Dr. Ricardo Brugés, oncólogo clínico del Instituto Nacional de Cancerología y Centro Javeriano de Oncología en Bogotá, Colombia, nos comenta sobre lo más destacado en cáncer de cabeza y cuello, presentado en el Congreso de ASCO 2024, resaltando los siguientes estudios: Nasofaringe · DIPPER: estudio fase III, multicéntrico, que aleatorizó 1:1 a pacientes con carcinoma nasofaríngeo localmente avanzado, de alto riesgo, que recibieron previamente quimioterapia de inducción con gemcitabina más cisplatino y quimiorradioterapia (QRT) concurrente, para recibir camrelizumab o terapia estándar. El objetivo primario fue la supervivencia libre de eventos (SLE). · Estudio fase III, multicéntrico, aleatorizado, que evaluó el uso de tislelizumab o placebo + gemcitabina y cisplatino seguido de QRT concurrente y tislelizumab adyuvante o placebo, en pacientes con carcinoma nasofaríngeo localmente avanzado. · Estudio fase III, prospectivo, aleatorizado, que incluyó a pacientes con carcinoma nasofaríngeo localmente avanzado para recibir rh-endostatina combinado con QRT concurrente vs. QRT concurrente sola. El objetivo primario fue la tasa de supervivencia libre de progresión. ·      CONTINUUM: estudio fase III, multicéntrico, aleatorizado, donde se incluyeron pacientes con carcinoma nasofaríngeo localmente avanzado, de alto riesgo, no metastásico para recibir el estándar de tratamiento (gemcitabina y cisplatino en quimioterapia de inducción más QRT con cisplatino), o sintilimab. El objetivo primario fue la SLE. Orofaringe · OpcemISA: estudio fase 2, aleatorizado, doble ciego, controlado con placebo, sobre la combinación de cemiplimab e ISA101b, una vacuna terapéutica que induce respuestas inmunitarias específicas a los antígenos oncogénicos E6 y E7 del HPV16, vs. cemiplimab solo en pacientes con cáncer de orofaringe recurrente/metastásico HPV16 positivo. ·Estudio fase II, multinacional, multicéntrico, abierto, que evaluó el uso de la terapia de vector HB-200 en combinación con pembrolizumab en pacientes con cáncer de orofaringe HPV 16 positivo. Se evaluó la seguridad, la respuesta de células T y la actividad antitumoral preliminar. ·Estudio fase III, multicéntrico, que comparó el uso de radioterapia de intensidad modulada vs. radioterapia de intensidad modulada con protones en pacientes con cáncer de orofaringe estadio III/IV. Fecha de grabación: 14 de junio 2024           Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.

This podcast is the audio version of the Gear Garage Live Show, where we answer submitted questions and talk all things whitewater. Topics and links that Zach talked about this episode River Hardware Answer Questions Some of the Questions that Zach covered in the Q&A section of this episode Topic: Illinois IK How low has the Illinois been run to your knowledge? I know Cronin and friends run it in the summer time but would like to get an idea of the CFS they/others have paddled. Is it still considered a 4+ river when the water is super low? Also, have you ever done the Deer Creek to Illinois section? Looks interesting. Thanks love the show. Topic: Boat Decals Rando question. What material do you guys use for the letters on your boat names to get them to stick so well? I wanted to add a name to our site raft and the best I could think of is a vinyl cut letters but don't know how well they will stay on. Thank you for the info Topic: PFD Help Hi - I'm hoping you can help me choose a life jacket. I do mostly class III-IV rivers, and occasionally a IV+ or V rapid. Because I'm not a great swimmer and because I have Parkinson's, I'd like a life jacket better than what guides typically provide. Should I buy a Type 1, Type 5, or something else?

La Dra. Flavia Morales, oncóloga médica de la Ciudad de México, México, nos comenta sobre lo más destacado en tumores ginecológicos, presentado en el Congreso de ASCO 2024, resaltando los siguientes estudios: RUBY: análisis post hoc de la supervivencia libre de progresión (SLP) y la supervivencia global (SG) del estudio fase III, multicéntrico, aleatorizado, doble ciego, el cual aleatorizó a pacientes con cáncer de endometrio recurrente o primario avanzado con deficiencia en la reparación de desajustes/inestabilidad microsatelital de alto nivel (dMMR/MSI-H) para recibir dostarlimab o placebo más carboplatino-paclitaxel, seguido de dostarlimab o placebo como monoterapia durante un máximo de 3 años. BrUOG 354: resultados finales del estudio aleatorizado, fase II, de nivolumab con o sin ipilimumab para pacientes con carcinomas de células claras de ovario y otros carcinomas de células claras extrarrenales previamente tratadas con al menos una terapia (sin inmunoterapia). Se evaluó la tasa de respuesta global de cada grupo por separado en la etapa 1 utilizando los criterios RECIST e iRECIST. CARACO: estudio aleatorizado, fase III, que investigó la omisión de la linfadenectomía en pacientes con cáncer de ovario epitelial avanzado en estadios III-IV de la FIGO, tratadas con cirugía citorreductora primaria o intervalada tras quimioterapia neoadyuvante. Se incluyeron pacientes sin ganglios linfáticos sospechosos antes y durante la cirugía. El objetivo primario fue la SLP y los objetivos secundarios incluían la SG, la seguridad, el resultado quirúrgico y la calidad de vida. AGO-OVAR 2.29: resultados finales de SG y SLP del estudio fase III, aleatorizado y doble ciego, diseñado para evaluar la eficacia y seguridad de la combinación de bevacizumab y quimioterapia no basada en platino con o sin atezolizumab en pacientes con cáncer de ovario recurrente que experimentaron su primera o segunda recaída dentro de los 6 meses después de completar quimioterapia a base de platino, o una tercera recaída independientemente del intervalo libre de tratamiento. Los objetivos primarios fueron la SG y la SLP, evaluados después de alcanzar 391 muertes en la población de intención de tratar. Fecha de grabación: 11 de junio de 2024.                       Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.

* Psalm 86 * Proverbs 20:1–25 * John 17:1–26 * Augsburg Confession, III–IV

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Domenica Lorusso to discuss the survival analysis of the PAOLA1 trial. Dr. Domenica Lorusso, MD, PhD, directs the Gynaecological Oncology Unit at Humanitas Hospital, Milan, and holds a Full Professorship in Obstetrics and Gynaecology at Humanitas University, Rozzano, Milan. She has led/participated in approximately 250 phase I-IV clinical trials. Currently overseeing more than 60 studies as Principal Investigator, Dr. Lorusso also chairs the Clinical Trials Committee of the MITO Group. She serves on the Board of Directors of the GCIG and is an active member of ENGOT, where she chairs the Gynecological Cancer Academy. Additionally, she sits on the Board of Directors of the ESGO. With around 300 international oncology publications and contributions to national and international treatment guidelines, her primary objectives are to ensure optimal patient care, foster clinical research, and advance international collaborations and education in the field.   Highlights: Bevacizumab plus olaparib has reported to increase PFS and OS in advanced stage III-IV, newly diagnosed, high grade serous and endometrioid HRD positive ovarian cancer in the maintenance setting  Exploratory analysis suggest that the advantage is particularly high in low risk patients (stage III withour residual tumor at primary surgery) where  a 5-year OS more  than 90% has been reported suggesting some of these patients may be cured In the HRp population the combination of olaparib-bevacizumab did non increase PFS and OS in comparison to bevacizumab alone The toxicity profile of the combination is in line with what expected with the single drugs

5-5-24 PM "Sovereignty in Salvation: Redemption Applied Pt. 2" Scripture Reading: John 3:1-2, Canons of Dort, III/IV.11, Forms & Prayers, 273 I. The Means of Regeneration A. The External Proclamation of the Gospel B. The Internal Operation of the Spirit II. The Effect of Regeneration A. Within the Soul B. Upon the Person III. The Result of Regeneration A. The Exercise of Faith B. The Attitude of Humility Rev. Greg Lubbers

4-28-24 PM "Sovereignty in Salvation: Redemption Applied Pt. 1" Sermon Text: Canons of Dort, III/IV.3 I. The Universal Corruption of Humanity A. The Object of the Universal Corruption B. The Cause of the Universal Corruption II. The Condemned Corruption of Humanity A. The Explanation of the Condemned Corruption B. The Reason for the Condemned Corruption III. The Paralyzing Corruption of Humanity A. The Description of the Paralyzing Condition B. The Remedy for the Paralyzing Condition Rev. Greg Lubbers

CME credits: 0.75 Valid until: 26-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/what-dermatologists-surgeons-need-to-know-adjuvant-treatment-for-resectable-stage-iiiiv-melanoma/24380/ This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.

Want access to more wisdom in time? Get access to over 1,500 +1's (just like this!) and 650+ Philosopher's Notes (distilling life-changing big ideas from the best self-development books ever written) and a LOT more with our Heroic Premium membership. Learn more and get 30 days free at https://heroic.us

Hoy continuamos con la carrera hacia el olimpo de los boxeadores con Rocky Balboa. En esta ocasión continuamos con las 3 secuelas que continuaron esta estelar saga, con sus altibajos. Para hablar de todo esto y mucho mas estamos por aqui Miguel Angel, Guillermo, David, Fer y el mamado. Esperamos que disfrutéis como siempre. Porque venimos de las estrellas!!! Mas enlaces de la guarida https://bio.link/laguaridadelsith

Francis's favorite nephews continue down the literary journey by reading some more of Mario Puzo's Godfather source material; books 2, 3 and 4 of the eponymous novel. Find out just what Johnny Fontaine was up to after Jack Woltz found a horse head in his bedsheets as well as life with Sonny as the Don.

“Beyond the Digest” episodes are bonus content to DermSurgery Digest, including reviews and commentary of interesting and relevant articles in dermatologic surgery literature. Articles featured in this episode include: McEvoy, A. M., Hippe, D. S., Lachance, K., Park, S., Cahill, K., Redman, M. W., Gooley, T., Kattan, M. W., & Nghiem, P. Merkel cell carcinoma recurrence risk estimation is improved by integrating factors beyond cancer stage: a multivariable model and web-based calculator. Journal of the American Academy of Dermatology 2023; 90(1), 208-210. https://doi.org/10.1016/j.jaad.2023.11.020 Alexander, N. A., Schaub, S. K., Goff, P. H., Hippe, D. S., Park, S. Y., Lachance, K., Bierma, M., Liao, J. J., Apisarnthanarax, S., Bhatia, S., Tseng, Y. D., Nghiem, P., & Parvathaneni, U. Increased risk of recurrence and disease-specific death following delayed postoperative radiation for Merkel cell carcinoma. Journal of the American Academy of Dermatology 2023; 90(2), 261–268. https://doi.org/10.1016/j.jaad.2023.07.1047 Lin, S. K., Deitermann, A., Haynes, D., Ricciardelli, K., Etzkorn, J. R., Miller, C. J., Higgins, H. W., Giordano, C. N., McMurray, S. L., Walker, J., Zhang, J., Nguyen, H. P., & Sobanko, J. F. Impact of time to surgical treatment in Merkel cell carcinoma: Surveillance, Epidemiology, and End Results–based population study. Journal of the American Academy of Dermatology 2023; 90(1), 208–210. https://doi.org/10.1016/j.jaad.2023.09.058 Massey, P. R., Wang, D. M., Murad, F., Mulvaney, P. M., Moore, K., Okhovat, J., Russell‐Goldman, E., Lin, W. M., Piris, A., Huilgol, S. C., Ruiz, E. S., & Schmults, C. D. Extensive Perineural Invasion vs Nerve Caliber to Assess Cutaneous Squamous Cell Carcinoma Prognosis. JAMA Dermatology 2023; 159(12), 1332. https://doi.org/10.1001/jamadermatol.2023.3703 Granger, E., Kim, E., Karn, E., Groover, M., Silk, A. W., Margalit, D. N., Tishler, R. B., Schoenfeld, J. D., & Ruiz, E. S. Definitive radiation therapy for inoperable stage III/IV cutaneous squamous cell carcinoma: A single-institution retrospective cohort study. Journal of the American Academy of Dermatology 2023; 90(1), 187–189. https://doi.org/10.1016/j.jaad.2023.09.030 Ahmady, S., Nelemans, P. J., Kelleners‐Smeets, N. W., Arits, A., De Rooij, M., Kessels, J. P. H. M., Essers, B. A., & Mosterd, K. Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in treatment of Bowen's disease: A multicenter randomized controlled trial. Journal of the American Academy of Dermatology 2023; 90(1), 58–65. https://doi.org/10.1016/j.jaad.2023.08.076 Paver, E., Ahmed, T., Burke, H., Saw, R. P., Stretch, J. R., Spillane, A. J., Shannon, K. F., Vergara, I. A., Elder, D. E., Lo, S., Thompson, J. F., & Scolyer, R. A. Prognostic significance of incipient ulceration in primary cutaneous melanoma. JAMA Dermatology 2023; 159(12), 1359. https://doi.org/10.1001/jamadermatol.2023.4193 Kwapnoski, Z., Doost, M. S., Vy, M., & Eisen, D. B. Aesthetic outcome of intermediate closure versus intermediate closure followed by 2-octyl cyanoacrylate: A randomized evaluator-blinded split-wound comparative effectiveness trial. Journal of the American Academy of Dermatology 2023. https://doi.org/10.1016/j.jaad.2023.10.028 Groover, M., Gupta, N., Granger, E., Forrester, V. J., Anstadt, E. J., Su, W., Heusinkveld, L. E., Chen, A., Lukens, J. N., Silk, A. W., Vidimos, A. T., Schoenfeld, J. D., Koyfman, S. A., & Ruiz, E. S. A multicenter real-world analysis of risk factors, therapeutics, and outcomes of patients with metastatic basal cell carcinoma. Journal of the American Academy of Dermatology 2024; 90(3), 545–551. https://doi.org/10.1016/j.jaad.2023.10.060 “Beyond the Digest” contributors include Dermatologic Surgery Digital Content Editor Naomi Lawrence, MD; “Beyond the Digest” co-host Yesul Kim, MD; Ami Greene, MD; Tara Jennings, MD; Sydney Proffer, MD; Devina Mehta, MD; and Catherine Motosko, MD. Please contact communicationstaff@asds.net.

Daniel Gonzalez joins the Star Wars Historians as they cover episodes three and four entitled "Time to Fly" & "Fallen Jedi!" Make sure to share the podcast with your friends and leave us a review!

Continuing with our Saw marathon, we get unhinged while talking about the next three films. It's crazy they really made ten of these. Support the show***Patreon: https://www.patreon.com/IMNerdSend listener letters to: imnerdpodcast@gmail.comLinktree: https://linktr.ee/IMNerdPodcastThanks for listening!

Editor’s Choice Paper: Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer Hosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:Kathleen N. Moore, MD, GOG-F and Stephenson Cancer Center at the University of Oklahoma Health Sciences Center

How many door knobs are too many door knobs? How do you bring mixed successes into D&D? And are the players not concerned that they stumbled into an international incident? All that and more on the Afterparty!   Check out the Conversation Pit channel on our Patreon discord and keep sending in questions!   Dive into our ship combat mechanics, classes from Mage Hand Press, the countries of Verda Stello, and other changes we've made for C3 HERE!   Sponsors - Betterhelp, where you can get 10% off your first month at betterhelp.com/jointheparty - Ravensburger CreArt, a new paint-by-numbers experience! Shop on Amazon, their website, or your local art supply store. - Bodoni Designs, where you can use code jointheparty for 10% off your purchase at BodoniDesigns.Etsy.com   Find Us Online - website: jointhepartypod.com - patreon: patreon.com/jointhepartypod - twitter: twitter.com/jointhepartypod - facebook: facebook.com/jointhepartypod - instagram: instagram.com/jointhepartypod - tumblr: jointhepartypod.tumblr.com - merch & music: jointhepartypod.com/merch   Cast & Crew - Game Master, Co-Producer: Eric Silver - Co-Host (Umbi), Co-Producer, Sound Designer, Composer: Brandon Grugle - Co-Host (Chamomile Cassis), Co-Producer: Julia Schifini - Co-Host (Troy Riptide), Co-Producer: Amanda McLoughlin - Theme Song: Lyrics by Eric Silver, music by Brandon Grugle. Vocals by Brandon Grugle, Lauren Shippen, Julia Schifini, Roux Bedrosian, Eric Silver, Tyler Silver, and Amanda McLoughlin. Available for purchase here. - Artwork: Allyson Wakeman - Multitude: multitude.productions   About Us Join the Party is an actual play podcast with tangible worlds, genre-pushing storytelling, and collaborators who make each other laugh each week. We welcome everyone to the table, from longtime players to folks who've never touched a roleplaying game before. Hop into our current campaign, a pirate story set in a world of plant- and bug-folk, or marathon our completed stories with the Camp-Paign, a MOTW game set in a weird summer camp, Campaign 2 for a modern superhero game, and Campaign 1 for a high fantasy story. And once a month we release the Afterparty, where we answer your questions about the show and how we play the game. New episodes every Tuesday.

DISCLAIMER: This episode was recorded during the 2023 WGA and SAG-AFTRA strikes. Without the labor of the writers and actors currently on strike, the series being discussed here wouldn't exist. If you're willing and able, please consider supporting the writers and actors currently on strike through Entertainment Community Fund at: ⁠⁠⁠⁠https://secure2.convio.net/afa/site/Donation2?df_id=8117&8117.donation=form1&mfc_pref=T⁠⁠⁠⁠. For more information on the strike please consult either the WGA or SAG-AFTRA FAQs at ⁠⁠⁠⁠https://t.co/c0FbeUqghK⁠⁠⁠⁠ or ⁠⁠⁠⁠https://t.co/baYKIOtqkZ⁠⁠⁠⁠. • • • Welcome to Triad of the Force's AHSOKA Reviews! Join Nani, and Gus on their limited series, covering all things Ahsoka (and Rebels, and Clone Wars!). Today, ⁠⁠⁠⁠⁠⁠⁠the gang reviews and analyzes the first two episodes of Season 1 of AHSOKA: Parts III, IV, & V | Time to Fly, Fallen Jedi, and Shadow Warrior. • • • Triad of the Force is a channel which was featured on the Podcast Stage at Star Wars Celebration 2022 and 2023, featuring Nani and Gus, lifelong Puerto Rican friends who after years of discussing the media they love, came together and created their show. Triad of the Force focuses their discussions on Star Wars, but their love for media spans everything from sci-fi, fantasy, CBMs, and beyond. From films to TV, from books to comic books, Triad of the Force looks at all media critically, from a Latine/x perspective. Joins us! Follow Triad Of The Force at: Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/TriadOfTheForce⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/triadoftheforce/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/c/TriadoftheForce/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ If you like us, get some merch and help the channel: TeePublic: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.teepublic.com/user/triad-of-the-force⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • • • Acknowledgement: The Intro and Outro music is the Triad of the Force Theme, composed and performed by Grushkov with full permission for use by Grushkov (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/Grushkov⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). • • • This channel is not affiliated in any way with Lucasfilm Ltd. LLC, The Walt Disney Company, or any of their affiliates or subsidiaries.

Wir kehren zur Prom Night Reihe zurück und besprechen für euch die Teil 3 bis 4. Während wir es im dritten Teil mit sehr viel Humor und wieder mit Mary Lou zu tun bekommen, lehrt uns in Deliver us from evil ein fieser Pastor das Fürchten. Ob die unterschiedlichen Rezepturen funktionieren? Findet es gemeinsam mit uns heraus!

III. The Role of the Psychotherapist IV. The Process of Illness The Psychotherapist is a teacher. Yet, the Teacher, the One who has transcended judgment altogether, and arisen into the totality of the egoless state of being, is needed as a Guide in the process. Otherwise, "sickness" is seen as a "reality," and the the illusion of sickness, made up of false "self-concepts" of victimhood and attack, is not undone.

Ya estamos de vuelta en esa otra galaxia que nos encanta, para disfrutar de las 4 ultimas películas de la tripulación original. Una despedida, llena de nostalgia y mucho fanservice, con algunas tramas muy divertidas y otras muy interesantes, pero para nada despreciables y que enriquecen la historia de la ciencia ficción. Para todo esto estamos hoy aqui Fran Prados, Guillem y Asier Huarte, aunque por estos lares se me conoce como El Mamado Lidel y desde mi puente de mando os advierto que vamos a despegar... Porque venimos de las estrellas!!! Mas enlaces de la guarida https://bio.link/laguaridadelsith

Dr. Shannon Westin, Dr. Lakshmi Sandhya, and Dr. Prasanth Ganesan discuss the use of olanzapine to treat chemotherapy-related anorexia, as recently published in JCO. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Shannon Westin: Hello, everyone, and welcome to another episode of JCO After Hours, the podcast where we get in-depth on manuscripts published in the Journal of Clinical Oncology. As always, I'm your host, Dr. Shannon Westin, GYN Oncologist and Social Media Editor for JCO. I'm very excited to be here today.  And please note that our participants do not have any conflict of interest.   So we are going to discuss a really exciting paper today entitled the "Randomized, Double-Blind, Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients with Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer." And this was published in the JCO on March 28, 2023, and has gotten a lot of excitement.  And so I'm very thrilled to have two of the authors with me today. First is Dr. Lakshmi Sandhya. She's a Junior Consultant at the SVICCAR Hospital in Tirupati, India. Welcome, Dr. Sandhya. Dr. Lakshmi Sandhya: Thank you so much for the opportunity to be here. Dr. Shannon Westin: And I also have the senior author here today, Dr. Prasanth Ganesan. He is a Professor in the Department of Medical Oncology at JIPMER, which is the Jawaharlal Institute of Postgraduate Medical Education and Research in Puducherry, India. Welcome, sir.  Dr. Prasanth Ganesan: Thank you. Thank you very much, Dr. Westin. It's good to be here. Thank you very much.  Dr. Shannon Westin: Great to have you both. So we're going to get right to it. I think this is an excellent paper and certainly something we see across many of our patients who are diagnosed with cancer and who are receiving treatment for cancer. But first, I want to level set. What is the true definition of chemotherapy-related anorexia, and really approximately how many patients do you think it impacts?  Dr. Prasanth Ganesan: As you know, anorexia itself is very common in advanced cancers. Almost like maybe 80%, 90% of patients have some form of anorexia. But at diagnosis, it depends on the type of cancers. Very high in upper GI cancers, esophagus, stomach, pancreas, or lung cancer. But when we talk about chemotherapy-related anorexia, we specifically mean anorexia that is brought on or probably worsened by chemotherapy. So this depends a lot on the regimen that is used. So studies in lung cancer, upper GI cancer that have used something like platinum agents, maybe as high as 50% to 80%. Now, the challenge is how much of it is contributed by the underlying cancer itself and how much of it is worsened by the chemotherapy. It's tough to say, but I think we all have seen that chemotherapy does kind of really increase the anorexia in many of these patients. So I would say the problem is common. Depends on the type of cancer, the type of agent being used, and also sometimes on how intently we are looking for it. Dr. Shannon Westin: You bring up a great point in really kind of making sure that we're screening our patients for it and understanding who's actually experiencing those things. And I do think putting it on our list of things that we, on a day-to-day basis, discuss with our patients is really relevant, although I will say sometimes we haven't done that because we don't have a good treatment. So that's what makes your paper so exciting. But before we get into the results of the paper, why don't we talk a little bit more about some of the factors that contribute to anorexia? Dr. Sandhya, I don't know if you want to elaborate a little bit on some of those. Dr. Lakshmi Sandhya: Yeah. So most important would be the cancer type and the type of chemotherapy agent being used. So, as we mentioned, some cancer types have high anorexia incidence even at baseline. So the most important and prominent would be the upper gastric cancers and the pancreatic and lung cancer. Among the chemotherapy types, I think the platinum agents are known to cause anorexia more often and also associated with nausea or vomiting. So anorexia and weight loss is not very common in other cancers like breast, if you see, or ovarian cancer during the therapy. In fact, there has been weight gain in most of the patients with breast cancer, and most of the data which comes from breast cancer show that weight loss is experienced only by around 5% of the patients. So we would say the factors contributing most commonly would be the type of cancer and the chemotherapy that is being used.  Dr. Shannon Westin: Yeah, I think it's a great point. As a gynecologic oncologist, we do a lot of platinum, but we balance it, especially in upfront with paclitaxel or taxanes and we're giving steroids as premeds for them. And so we definitely see patients expecting to lose weight and instead actually getting hungry with the steroid use and eating to some degree.  Dr. Prasanth Ganesan: So I just want to add that even targeted agents, when you use something like sunitinib or everolimus, some of these agents, even they have got anorexia, probably 20% to 30%. So we did not include them in our study, but I'm just saying that even with targeted agents, we do get anorexia, at least some of them. So it's a problem across them. Dr. Shannon Westin: Yeah, we've been using PARP inhibitors and definitely can see that nausea, vomiting, and anorexia in that population. So I appreciate you making a point that that wasn't included but could be potentially extrapolated here. And then I guess the other question that I have is how does anorexia impact cancer-related outcomes? Does it have an impact in that way? Dr. Prasanth Ganesan: I believe it does, but it's probably not in a direct sort of way. So anorexia is strongly associated with weight loss and some amount of cachexia, and weight loss per se has been associated with poor outcomes across the board. There's a lot of data, especially in lung, upper GI cancers, and even head and neck cancer where weight loss before or during therapy has been associated with poor survival impact. So, again—in pancreatic cancer, it's associated with poor survival. So it's difficult to pin the weight loss only on anorexia here because weight loss is often multifactorial, but yeah, anorexia is probably a significant factor which is also adding to that. So I would say indirectly, yes, anorexia has an impact on cancer-related outcomes. Yes.  Dr. Shannon Westin: And I guess just getting into kind of what we can do before we get into the novel findings in your study, I know we've tried to talk about some dietary-related interventions that we can utilize to combat anorexia. Anything that you all have found to be most helpful from a diet standpoint?  Dr. Lakshmi Sandhya: So, from the diet standpoint, I would say dietary counseling is generally recommended for all the patients. To be very frank, we don't usually have a dietitian to spare at our outpatient clinic to counsel all the patients. So this is not something we are able to practice in the clinic. But in this trial, of course, we had a dietitian who counseled all the patients, and she gave them a diet chart to follow and gentle advice on what item to use and which is good, specifically emphasizing on high-calorie and high-protein diet. So we did not find that any particular dietary intervention is impactful. If you've seen various studies on dietary intervention, they have shown mixed results on improvement of anorexia or weight gain. So we're not sure whether dietary counseling particularly has impacted the results. Dr. Prasanth Ganesan: Yes. Dr. Shannon Westin: Okay. And then I imagine that would be one of the reasons that led to your exploration of this agent of olanzapine to treat chemotherapy-related anorexia. And can you just walk us through any data that existed kind of prior to your study to support this work? Dr. Prasanth Ganesan: Yeah, definitely. I think olanzapine has been in the news for the last decade or so because we've been using it consistently for vomiting and nausea in patients getting emetogenic therapies. So there are at least three studies which we found for olanzapine in cancer anorexia. I think one was from Dr. Navari, and he had done a randomized trial comparing megestrol with megestrol plus olanzapine. And this was done in patients with advanced cancers, and they found about 35% of the patients in the olanzapine group had additional weight gain. So it was useful. And this was not a very recent study. It's almost done about 10 years back. Dr. Shannon Westin: Oh, wow. Dr. Prasanth Ganesan: Then, after that, there was an interesting phase I study by Dr. Naing, and that was from MD Anderson, and that looked at various doses of olanzapine also. And that was interesting for us because that's where we got our starting dose of 2.5 mg because even at this dose, there was an effect on anorexia. So that was a very useful study because we were also trying to figure out what is the best dose to use in our trial. So that's why we went with the 2.5 mg.  Dr. Shannon Westin: That's great. I know everyone's excited to hear about the results. So, Dr. Sandhya, do you want to walk us through the design of the study and maybe how you chose your patient population? I think you've already kind of hinted at it, taking people that at baseline have high levels of anorexia.  Dr. Lakshmi Sandhya: Yes, sure. So this was designed as a phase III randomized blinded trial. So we used olanzapine in one arm and the matched placebo in another. So we gave olanzapine at a dose of 2.5 mg once a day for 12 weeks. And similarly, a placebo which looked similar was given to the other group. So we assessed for weight gain as an objective measure and improvement in appetite as one of the endpoints, which is more of a subjective measure. And we wanted to focus on population where the problem of anorexia was maximum. So we focused on upper GI, lung and pancreas, and biliary tract cancers to make it more uniform when it comes to anorexia. Dr. Prasanth Ganesan: Just to add a point that, even though we had included three or four types of cancer, almost 60% of our patients were actually gastric cancer patients because that probably reflects the profile of patients that we see at our center. It's a very common cancer in our place, and the next common was the lung cancer. We had only about 15% of patients who had pancreaticobiliary cancer. Dr. Shannon Westin: That makes sense. Obviously, wherever we're enrolling is what we're going to see, but I think hopefully these data can be extrapolated across all cancer types. So you mentioned that your primary endpoint was weight loss as well as the improved appetite. Can you walk us through, Dr. Sandhya, what you found? What were your results? Dr. Lakshmi Sandhya: So we had two primary endpoints. One was weight gain, and the other was improvement in appetite. So we wanted to use weight gain, as I said, since we felt that it is more of an objective measure than measuring anorexia. And olanzapine in our trial improved weight more than 5% from baseline in 60% of the patients in the olanzapine group and 9% in the placebo. Correspondingly, we have also measured improvement in appetite by using various questionnaires, which are validated. So one was visual analog scale, and the other was FAACT AC subscale, which we used during this trial. So yes, olanzapine worked well. We had hoped to show improvement in weight in about 30%, but surprisingly, we found that the weight gain was about 60% in the olanzapine group.  Dr. Shannon Westin: That's so great. It's always nice when you outperform your wildest dreams. So congratulations. Were there other secondary endpoints you observed that were impacted by the olanzapine?  Dr. Prasanth Ganesan: Yeah. So we did have a bunch of secondary endpoints because, again, we were worried when we started off because this is a subjective endpoint and we're not really sure how it's going to pan out. So we looked at some endpoints like quality of life, obviously, and we also had some nutritional assessment with the SDA and consistently, all of these showed improvement with the olanzapine. And what is most interesting for us was the grade III/IV side effects of the chemotherapy regimens, and these were reduced in the olanzapine. So this was something which we were looking for because consistently—we had also done some earlier studies in elderly populations where we found that the nutrition was an important factor in determining the toxicities of therapy. So that's why we wanted that as an endpoint.  And in fact, we found that patients who started at lower doses in cycle one due to poor performance status and nutrition, many of them could actually increase their dose in their subsequent cycles and this was more commonly seen in the olanzapine arm. So this was something which was very pleasant and which was something which we found was very interesting. So we could deliver more better chemotherapy intensity in these patients, thanks to their better nutrition.  Dr. Shannon Westin: That's so exciting. Such a nice concrete thing for patients as well. I mean, obviously being able to gain weight is something that they could see and having that appetite, but knowing that they had less side effects from their chemo as well is such an important impact. I guess, on the converse side, were there any negative impacts to the olanzapine?  Dr. Lakshmi Sandhya: Not really. We specifically asked patients about olanzapine-induced side-effects like drowsiness. At this dose of 2.5 mg per day, we found very little side-effects which would be attributed to olanzapine. As we mentioned, overall side-effects were also lowered in olanzapine arm. So with short duration of three months and at this dose, we believe that olanzapine is fairly safe. Dr. Shannon Westin: And that's great. And I'd be remiss—especially here in the States, this is high discussion around financial toxicity. As I recall, it's a pretty inexpensive agent. Is there any kind of negative financial impact for the use of this drug?  Dr. Prasanth Ganesan: Yeah, this is the best part. In India, for three months, olanzapine costs about 300 rupees. That would be like $4 or something for three months of therapy. I think that's pretty easily affordable across the board. Most patients here can easily buy this. And I'm not sure about the cost in the US, but I'm guessing it would not be too high. It's been around for some time. It should be out of patent and things like that. So I think it's a very inexpensive drug.  Dr. Shannon Westin: Yeah, we like that, like reuse of an old drug to do something good. The other question I had for you all is just any thoughts about how these results might compare to other things that we use, like glucocorticoids or progestational agents? I know we didn't have that as a comparator, but just your thoughts on that. Dr. Prasanth Ganesan: So, in terms of efficacy in reducing anorexia, it's difficult to compare because, if you see the studies of steroids and megestrol, most of them have been done by patients with more advanced cancers, not necessarily patients who are getting chemotherapy in the front line. But we think the side-effect profile is what gives an advantage to olanzapine because three months of steroids, even if you say lower doses of dex at 4mg or something, which I would want to use in a newly diagnosed cancer patient. Megestrol also seems to have problems like DVT and is actually much more expensive, at least in our context. I mean, if you compare with these aspects, I would definitely put olanzapine ahead, but as you said, this is not a direct comparison between those so-called existing agents. Dr. Shannon Westin: Yeah, I think that's a very thoughtful answer, but I think something we just needed to cover, even though we know that it wasn't a randomized trial between those two. Any limitations, Dr. Sandhya, on these results? Anything that you wish you had done a little differently? Dr. Lakshmi Sandhya: Yeah. As such, it is applicable only in the context of upper GI and lung cancers, as we have mostly included upper GI and lung cancers, and most of the patients, almost two-thirds of the patients included in our study, were gastric cancers. So also the duration that we used was only for 12 weeks. So we don't know whether longer duration will benefit more or harm. And the sustainability of weight beyond 12 weeks, we have not actually looked into. So, yeah, maybe these are few limitations that we can think about. Dr. Shannon Westin: That's very true. And I think that—I mean, obviously, when we design trials, we have to have a limit. Do you have plans—are you able to follow these patients out a little further? Do you know if clinically they're continuing it off-trial?  Dr. Prasanth Ganesan: So we have done that. So we have been following them for their survival data, and we just completed the analysis. So I think we have to really publish that next. So it is looking interesting. So some interesting data there. So that's something which we found it very exciting. Dr. Shannon Westin: Okay, good. Dr. Prasanth Ganesan: So that is something which is out there. And we also looked at some data on improvement of their muscle mass and on their CAT scans, we looked at that. So that's also something which we are trying to analyze and see whether we can have more concrete or objective endpoints in terms of improvement of the muscle mass and adipose tissue and things like that. Dr. Shannon Westin: Okay, good. Well, we'll look forward to that in a future version of the JCO, I hope. I guess the last thing is where do we go from here? You kind of hinted at this a little bit. I'm kind of bummed because I was ready to start implementing this in my clinic tomorrow. Dr. Prasanth Ganesan: So it's just safe, it's effective, and it's cheap. So I don't see any reason we should not start implementing something like this straightaway. I use it quite commonly, definitely for patients who are part of the trial population. And even for any patients with advanced cancer on or off chemotherapy with anorexia or weight loss, I'm comfortable to use olanzapine at least for a short term. And many patients at least they come back and say that it does help them. And I've not seen any side-effects at this dose of olanzapine. So it seems very safe to use. I'm comfortable to put it in the clinic right away.  Dr. Shannon Westin: Dr. Sandhya, what do you think?  Dr. Lakshmi Sandhya: I feel, in this trial, we came across the safety part of it and also the affordability part of it, and definitely it has been very encouraging results, so yeah. So, day-to-day practice, it can be used. Dr. Shannon Westin:  Well, great. I think this is super-educational, and I hope everyone else is just as convinced as I am how important this work was and how potentially impactful it will be for our patients. I just want to again thank these wonderful physicians and researchers. Dr. Sandhya, Dr. Ganesan, thank you so much for your time and a little bit of a late time for this taping across the globe. So thanks again for being here. Dr. Prasanth Ganesan: Thanks, Dr. Westin, for giving us this chance.  Dr. Lakshmi Sandhya: Thank you so much. Dr. Shannon Westin: So, again, y'all, this has been JCO After Hours discussing the important paper, "Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer,” published March 28th, ‘23. We are just so grateful that you joined us and hope you'll check out the other podcast offerings on the website. Take care. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

* Psalm 86 * Proverbs 20:1–25 * John 17:1–26 * Augsburg Confession, III–IV

We pick back up with new best friends Gilgamesh and Endiku as they head out to best the best of the Cedar Forrest. Andrea, Brandon, and Matt discuss more connections to the Bible and other ancient mythology.Join the discussion on CIRCE Circle: https://circe.circle.so/c/overdue-classics/Send questions or comments to podcasts@circeinstitute.orgFind the books here: https://bookshop.org/lists/overdue-classics Hosted on Acast. See acast.com/privacy for more information.

Church of Jesus Christ Study Session seeks to generate reflection about areas in the Restored Gospel. Whether it's Come Follow Me, a General Conference talk or a recent Gospel Topic, hopefully you'll find something to keep the Spirit of Christ in your life. Twitter - @mattsroberts90 ldsstudysession@gmail.com You can also join the discussion in the Facebook Group 'Church of Jesus Christ Study Session with Come Follow Me'. You can purchase my book, From Father to Child: Raising a Child to Spiritual Strength in Generation Alpha at the link here: https://www.amazon.co.uk/Father-Child-Spiritual-Strength-Generation-ebook/dp/B08DRLWWZD/ref=mp_s_a_1_3?dchild=1&keywords=from+father+to+child&qid=1596387393&sr=8-3

Cornelius Boots is a woodwinding pioneer, composer and root philosopher. He is a nanotheist and elemental-nature lover. After a 30-year career of high-caliber jazz, classical, rock and experimental music activities (on multiple woodwinds with a focus on the bass clarinet), Boots has now positioned himself at the crossroads of personal expression and divine revelation, exclusively playing bamboo shakuhachi (jinashi/hotchiku) and its baritone brother, Taimu. He is the founder of Black Earth Shakuhachi School, and composes music for The Heavy Roots Shakuhachi Ensemble, the world's first bass shakuhachi group. (For bass clarinet and Edmund Welles-related information, go here.) In 2018, he was a World Shakuhachi Competition finalist and featured at Sony PlayStation's E3 (LA). Also in 2018, he performed at the World Bamboo Congress (Xalapa, Mexico) and the World Shakuhachi Festival (London). In 2019, Boots founded the Heavy Roots Shakuhachi Ensemble, debuting at SF Music Day. In 2020, the Boots received a Musical Grant Program Award from InterMusic SF to compose four movements of Wood Prophecy, a woodwind chamber saga for the Heavy Roots. The music video for his composition “Green Swampy Water” won Best Music Video in the Tokyo International Short Film Festival in January 2021. Cornelius is a sought-after composer, performer, and teacher. He is reshaping the landscape of modern shakuhachi performance and teaching through introducing a robust body of new compositions and a set of expressive signature techniques. Music from Today's episode by Cornelius Boots “Black Earth” from Sacred Root: Kung Fu Flute & Buddhist Blues (Shakuhachi Unleashed Vol. III) “IV. Dark Hallow” and “V. Wood Prophecy” from Wood Prophecy

Go online to PeerView.com/NHA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapy is now a highly efficacious management tool for melanoma, including in resectable stage III/IV disease, where its use is supported by phase 3 evidence and current practice guidelines. This “Clinical Consults” activity, taken from a recent surgical oncology live event, features expert-led case discussions that illustrate how to deliver effective care with established and emerging immune-based modalities in surgical settings. Linked mini lecture segments cover topics such as adjuvant immunotherapy in stage II/III melanoma; efficacy, safety, and dosing information on neoadjuvant immunotherapy; and emerging immune-based treatments in resectable melanoma (eg, PD-1/LAG-3 combinations). Watch today to learn how to identify optimal candidates for immunotherapy, address treatment selection and dosing considerations, and effectively manage immune-related events. Upon completion of this activity, participants should be better able to: State current evidence and guideline recommendations surrounding the use of adjuvant and neoadjuvant immunotherapy for resectable or potentially resectable melanoma, including stage II, III, and IV disease; Develop a treatment plan that includes adjuvant and neoadjuvant immunotherapeutic options for patients with resectable melanoma, including those with and without BRAF-mutant disease; and Implement strategies to mitigate immune-related adverse events in patients with melanoma who are receiving immunotherapy in conjunction with surgery.

Go online to PeerView.com/NHA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapy is now a highly efficacious management tool for melanoma, including in resectable stage III/IV disease, where its use is supported by phase 3 evidence and current practice guidelines. This “Clinical Consults” activity, taken from a recent surgical oncology live event, features expert-led case discussions that illustrate how to deliver effective care with established and emerging immune-based modalities in surgical settings. Linked mini lecture segments cover topics such as adjuvant immunotherapy in stage II/III melanoma; efficacy, safety, and dosing information on neoadjuvant immunotherapy; and emerging immune-based treatments in resectable melanoma (eg, PD-1/LAG-3 combinations). Watch today to learn how to identify optimal candidates for immunotherapy, address treatment selection and dosing considerations, and effectively manage immune-related events. Upon completion of this activity, participants should be better able to: State current evidence and guideline recommendations surrounding the use of adjuvant and neoadjuvant immunotherapy for resectable or potentially resectable melanoma, including stage II, III, and IV disease; Develop a treatment plan that includes adjuvant and neoadjuvant immunotherapeutic options for patients with resectable melanoma, including those with and without BRAF-mutant disease; and Implement strategies to mitigate immune-related adverse events in patients with melanoma who are receiving immunotherapy in conjunction with surgery.

Go online to PeerView.com/NHA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapy is now a highly efficacious management tool for melanoma, including in resectable stage III/IV disease, where its use is supported by phase 3 evidence and current practice guidelines. This “Clinical Consults” activity, taken from a recent surgical oncology live event, features expert-led case discussions that illustrate how to deliver effective care with established and emerging immune-based modalities in surgical settings. Linked mini lecture segments cover topics such as adjuvant immunotherapy in stage II/III melanoma; efficacy, safety, and dosing information on neoadjuvant immunotherapy; and emerging immune-based treatments in resectable melanoma (eg, PD-1/LAG-3 combinations). Watch today to learn how to identify optimal candidates for immunotherapy, address treatment selection and dosing considerations, and effectively manage immune-related events. Upon completion of this activity, participants should be better able to: State current evidence and guideline recommendations surrounding the use of adjuvant and neoadjuvant immunotherapy for resectable or potentially resectable melanoma, including stage II, III, and IV disease; Develop a treatment plan that includes adjuvant and neoadjuvant immunotherapeutic options for patients with resectable melanoma, including those with and without BRAF-mutant disease; and Implement strategies to mitigate immune-related adverse events in patients with melanoma who are receiving immunotherapy in conjunction with surgery.

Go online to PeerView.com/NHA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapy is now a highly efficacious management tool for melanoma, including in resectable stage III/IV disease, where its use is supported by phase 3 evidence and current practice guidelines. This “Clinical Consults” activity, taken from a recent surgical oncology live event, features expert-led case discussions that illustrate how to deliver effective care with established and emerging immune-based modalities in surgical settings. Linked mini lecture segments cover topics such as adjuvant immunotherapy in stage II/III melanoma; efficacy, safety, and dosing information on neoadjuvant immunotherapy; and emerging immune-based treatments in resectable melanoma (eg, PD-1/LAG-3 combinations). Watch today to learn how to identify optimal candidates for immunotherapy, address treatment selection and dosing considerations, and effectively manage immune-related events. Upon completion of this activity, participants should be better able to: State current evidence and guideline recommendations surrounding the use of adjuvant and neoadjuvant immunotherapy for resectable or potentially resectable melanoma, including stage II, III, and IV disease; Develop a treatment plan that includes adjuvant and neoadjuvant immunotherapeutic options for patients with resectable melanoma, including those with and without BRAF-mutant disease; and Implement strategies to mitigate immune-related adverse events in patients with melanoma who are receiving immunotherapy in conjunction with surgery.

Go online to PeerView.com/NHA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapy is now a highly efficacious management tool for melanoma, including in resectable stage III/IV disease, where its use is supported by phase 3 evidence and current practice guidelines. This “Clinical Consults” activity, taken from a recent surgical oncology live event, features expert-led case discussions that illustrate how to deliver effective care with established and emerging immune-based modalities in surgical settings. Linked mini lecture segments cover topics such as adjuvant immunotherapy in stage II/III melanoma; efficacy, safety, and dosing information on neoadjuvant immunotherapy; and emerging immune-based treatments in resectable melanoma (eg, PD-1/LAG-3 combinations). Watch today to learn how to identify optimal candidates for immunotherapy, address treatment selection and dosing considerations, and effectively manage immune-related events. Upon completion of this activity, participants should be better able to: State current evidence and guideline recommendations surrounding the use of adjuvant and neoadjuvant immunotherapy for resectable or potentially resectable melanoma, including stage II, III, and IV disease; Develop a treatment plan that includes adjuvant and neoadjuvant immunotherapeutic options for patients with resectable melanoma, including those with and without BRAF-mutant disease; and Implement strategies to mitigate immune-related adverse events in patients with melanoma who are receiving immunotherapy in conjunction with surgery.

Church of Jesus Christ Study Session seeks to generate reflection about areas in the Restored Gospel. Whether it's Come Follow Me, a General Conference talk or a recent Gospel Topic, hopefully you'll find something to keep the Spirit of Christ in your life. Twitter - @mattsroberts90 ldsstudysession@gmail.com You can also join the discussion in the Facebook Group 'Church of Jesus Christ Study Session with Come Follow Me'. You can purchase my book, From Father to Child: Raising a Child to Spiritual Strength in Generation Alpha at the link here: https://www.amazon.co.uk/Father-Child-Spiritual-Strength-Generation-ebook/dp/B08DRLWWZD/ref=mp_s_a_1_3?dchild=1&keywords=from+father+to+child&qid=1596387393&sr=8-3

To unlock the full episode, join the Frightday Society at http://thefrightdaysociety.org for access to this, and much, much more.   Folks...we've arrived. Another typical, mid-April end to a bracket-style competition. The best PG-13 horror film has been determined (with the help of a surprise tie-breaking guest), and all that's left...is to listen and find out.   Do you agree with our thoughts? What's the next bracket we should do?

In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. David M. Gershenson to discuss updates on germ cell tumors. Dr. Gershenson is Professor and former Chair of the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center. His major focus is on the clinical and translational research or rare ovarian cancers. Highlights: - The treatment of malignant ovarian germ cell tumor has evolved over the last 5 decades to represent one of our most remarkable success stories, with cure in 95+% of patients with stage I/II and approximately 75% of patients with stage III/IV. - AGCT1531 is a very important trial, which, if positive, will reduce toxicity by extending surveillance to patients with stage IA or IB malignant ovarian germ cell tumors, including grade 2 and 3 immature teratomas, yolk sac tumors, and non-gestational choriocarcinomas and will result in the substitution of carboplatin for cisplatin in the regimen for treatment of stage IC-III. - Fertility-sparing surgery is possible in the majority of young patients with malignant ovarian germ cell tumor, related to the following: a) 95% are confined to one ovary ; b) approximately 2/3s are stage I; and c) most patients are in their teenage years, 20s, and 30s and have not completed childbearing. - Major controversies differentiating the treatment of children and adults by pediatric oncologists/pediatric surgeons and gynecologic oncologists, respectively, include the extent of surgical staging and the role of postoperative chemotherapy in patients with pure immature teratoma. - For patients with malignant ovarian germ cell tumors who recur following primary therapy, BEP is recommended for those who have been treated with surgery alone. For those who have previously received BEP, standard management generally includes high-dose chemotherapy with stem cell rescue. - Aspects of management of malignant ovarian germ cell tumors that require further study include the role of neoadjuvant chemotherapy and the role of secondary cytoreductive surgery.

Church of Jesus Christ Study Session seeks to generate reflection about areas in the Restored Gospel. Whether it's Come Follow Me, a General Conference talk or a recent Gospel Topic, hopefully you'll find something to keep the Spirit of Christ in your life. Twitter - @mattsroberts90 ldsstudysession@gmail.com You can also join the discussion in the Facebook Group 'Church of Jesus Christ Study Session with Come Follow Me'. You can purchase my book, From Father to Child: Raising a Child to Spiritual Strength in Generation Alpha at the link here: https://www.amazon.co.uk/Father-Child-Spiritual-Strength-Generation-ebook/dp/B08DRLWWZD/ref=mp_s_a_1_3?dchild=1&keywords=from+father+to+child&qid=1596387393&sr=8-3

Church of Jesus Christ Study Session seeks to generate reflection about areas in the Restored Gospel. Whether it's Come Follow Me, a General Conference talk or a recent Gospel Topic, hopefully you'll find something to keep the Spirit of Christ in your life. Twitter - @mattsroberts90 ldsstudysession@gmail.com You can also join the discussion in the Facebook Group 'Church of Jesus Christ Study Session with Come Follow Me'. You can purchase my book, From Father to Child: Raising a Child to Spiritual Strength in Generation Alpha at the link here: https://www.amazon.co.uk/Father-Child-Spiritual-Strength-Generation-ebook/dp/B08DRLWWZD/ref=mp_s_a_1_3?dchild=1&keywords=from+father+to+child&qid=1596387393&sr=8-3

An interview with Dr. William Tew from Memorial Sloan Kettering Cancer Center in New York, NY, lead author on "Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update." Dr. Tew reviews changes to the recommendations for PARPi therapy for patients with epithelial ovarian cancer, and the outstanding questions in the field. For more information, visit www.asco.org/gynecologic-cancer-guidelines. TRANSCRIPT Brittany Harvey: Hello, and welcome to the ASCO Guidelines Podcast series, brought to you by the ASCO Podcast Network, a collection of nine programs covering a range of educational and scientific content, and offering enriching insight into the world of cancer care. You can find all the shows, including this one, at asco.org/podcasts.  My name is Brittany Harvey, and today, I'm interviewing Dr. William Tew from Memorial Sloan Kettering Cancer Center in New York, New York; lead author on “PARP Inhibitors in the Management of Ovarian Cancer, ASCO Guideline Rapid Recommendation Update.” Thank you for being here, Dr. Tew.  Dr. William Tew: Thank you, Brittany. Glad to be here.  Brittany Harvey: Great. Then first, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline.  The full conflict of interest information for this guideline panel is available online with the publication of the guideline in the Journal of Clinical Oncology.  Dr. Tew, do you have any relevant disclosures that are directly related to this guideline topic?  Dr. William Tew: I do not.  Brittany Harvey: Thank you. Then let's get into the content of this rapid update. So, what prompted this rapid update to the ASCO Guideline on PARP inhibitor therapy in the management of ovarian cancer, which was previously published in 2020?  Dr. William Tew: Yeah, there's been rapid change in the use of PARP inhibitors over the last five years. We have seen marked improvements and patient outcomes with the use of PARP inhibitors in the maintenance setting and treatment settings.  And new data has developed specifically in the last three months that we felt it was really important to help our patients and their providers, give them the best and safest treatments with PARP inhibitors.  Brittany Harvey: Understood. So, then based off this new data that you mentioned, what are the updated recommendations from the expert panel?  Dr. William Tew: Well, there's a few. First, at ASCO 2022 in June, there was the ATHENA-MONO phase III randomized control trial that was presented and published looking at rucaparib monotherapy in patients with stage III-IV epithelial ovarian cancer who were in complete or partial response to platinum-based therapy and in remission. And then studies showed a significant improvement in progression-free survival.  And that's what first prompted the update of the guideline. We felt it was an important note that now, there are three PARP inhibitors that are approved and showing significant benefit in patients in the first remission setting. And those are olaparib, niraparib, and rucaparib.  And then as we were working on the guideline, there has been several updates provided primarily through Dear Doctor letters directed through the U.S. FDA, as well as different labeling changes that were made to different PARP inhibitors.  However, the changes that were made are in the settings outside of the first line setting. So, we are talking about patients who had recurrence of their ovarian cancer and where PARPs are being used either as treatment or as a maintenance strategy after completion of another round of platinum-based treatment.  Brittany Harvey: Understood. So, these sound like important updates to the recommendations. So, then what should clinicians know as they implement these updated recommendations?  Dr. William Tew: Well, I think first and foremost, PARP inhibitors are a really critical treatment strategy for our patients. And patients that benefit the most from PARP inhibitors are women with a germline or somatic mutation in the BRCA gene. These are the patients that are going to benefit the most.  And then I think where the confusion lies is how best to use PARP inhibitors in patients that don't have a BRCA mutation. These groups of patients kind of fall into different categories.  One, a group of patients that have what's called homologous repair deficiency, or those patients that don't have a BRCA gene or have a BRCA gene mutation, or have this HRD positive status.  The emerging data that has been presented is really focused on mostly these patients, this non-BRCA patient population. And again, I want to just be cautious here because this is all evolving data and I suspect further data is going to emerge over the coming months and years.  And we wanted to give some flexibility as far as how patients and their providers use PARP inhibitors, but we felt given that this new emerging data specifically with signals affecting survival, was important to outline to our community.  Brittany Harvey: Excellent. And then you've just touched on those who respond best to PARP inhibitor therapy, but how does this rapid update impact patients with epithelial ovarian cancer?  Dr. William Tew: Yeah, I think what we described and outlined in this updated guideline is that, one, as a general rule, PARP inhibitors are not particularly recommended in patients as a treatment.  That is, if patients have recurrence of their ovarian cancer, using PARP inhibitors as a treatment rather than a maintenance strategy does not offer significant benefit and may have some survival decrements. At least, this is the data that we are following.  And so, as a general recommendation, we're expressing caution in the use of PARP inhibitors in patients that have platinum sensitive recurrence as a treatment. And we are continuing to recommend (this was in the initial 2020 guideline) that PARP inhibitor monotherapy is not recommended for patients with platinum-resistant recurrent ovarian cancer or BRCA wild-type.  The other broad category is PARP inhibitor maintenance, and where we've made some adjustments in the guideline is as far as the strength and the overall recommendations of the use of PARP inhibitors after completion of platinum-based therapy in the recurrent setting.  And specifically, we're expressing caution and the use of PARP inhibitors, particularly for those that have BRCA wild-type, meaning they don't have a germline or somatic BRCA mutation, and expressing some caution in patients that are just homologous repair deficient score positive.  Brittany Harvey: Well, I appreciate you reviewing the updated data that the panel reviewed and what those new recommendations that you all made.  So, you just mentioned that further data may emerge over the coming days and years. So, what are the outstanding questions regarding PARPi therapy in the management of ovarian cancer?  Dr. William Tew: Well, I think a few things. One, the way PARP inhibitors have been developed was first in the recurrent setting as a treatment, then in the recurrent setting as a maintenance, and most recently, in the frontline treatment as maintenance therapy.  And what we're seeing as this data evolves is that PARP inhibitor has remain a very important treatment strategy in the first line maintenance group. And patients with BRCA mutations continue to have significant improvements and outcomes.  But what I think the data that we're following closely, is what about those patients that have recurrent ovarian cancer and where PARPs now are being used as treatment and maintenance — we're seeing that as a treatment, there may be harm, although, again, cautioned because of the data that is used. There's faults with how we look at this data.  But really, these subgroups of patients, specifically those patients without a positive HRD score or those patients without a BRCA mutation, is the benefit going to still outweigh the risk in the PARP inhibitor maintenance setting, particularly in the recurrent setting.  Brittany Harvey: Yes, those are important questions and I'm sure the panel will keep their eye on those to update the guideline further as needed.  So, I want to thank you so much for your work on this rapid update, and thank you for your time today, Dr. Tew.  Dr. William Tew: You're welcome.  Brittany: And thank you to all of our listeners for tuning into the ASCO Guidelines Podcast series. To read the full guideline, go to www.asco.org/gynecologic-cancer-guidelines.   You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in iTunes or the Google Play Store.  If you have enjoyed what you've heard today, please rate and review the podcast, and be sure to subscribe so you never miss an episode.  Voiceover: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care, and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy, should not be construed as an ASCO endorsement.     

Church of Jesus Christ Study Session seeks to generate reflection about areas in the Restored Gospel. Whether it's Come Follow Me, a General Conference talk or a recent Gospel Topic, hopefully you'll find something to keep the Spirit of Christ in your life. Twitter - @mattsroberts90 ldsstudysession@gmail.com You can also join the discussion in the Facebook Group 'Church of Jesus Christ Study Session with Come Follow Me'. You can purchase my book, From Father to Child: Raising a Child to Spiritual Strength in Generation Alpha at the link here: https://www.amazon.co.uk/Father-Child-Spiritual-Strength-Generation-ebook/dp/B08DRLWWZD/ref=mp_s_a_1_3?dchild=1&keywords=from+father+to+child&qid=1596387393&sr=8-3

Dr Monk discusses pertinent efficacy and safety data from the ATHENA-MONO trial, which evaluated first-line maintenance treatment with rucaparib in patients with stage III-IV high-grade ovarian cancer.

The following question refers to Section 6.2 of the 2021 ESC CV Prevention Guidelines. The question is asked by Dr. Christian Faaborg-Andersen, answered first by Houston Methodist medicine resident Dr. Najah Khan, and then by expert faculty Dr. Jaideep Patel. Dr. Patel recently graduated from Virginia Commonwealth University cardiology fellowship and is now a preventive cardiologist at the Johns Hopkins Hospital. The CardioNerds Decipher The Guidelines Series for the 2021 ESC CV Prevention Guidelines represents a collaboration with the ACC Prevention of CVD Section, the National Lipid Association, and Preventive Cardiovascular Nurses Association. Question #18 A 60-year-old Black woman with a history of hypertension and heart failure with reduced ejection fraction (EF 40%) presents to clinic for follow-up. She is currently doing well with NYHA class II symptoms. She is taking carvedilol 25 mg BID, sacubitril/valsartan 97/103 mg BID, and spironolactone 25 mg daily, all of which have been well tolerated. In clinic, her BP is 125/80 mmHg, and her HR is 55 bpm. Routine labs are within normal limits including Cr of 1.0, K of 4.0, and HbA1c of 6.0. What is the most appropriate next step in her management? A. No change in management B. Reduce beta blocker C. Add an SGLT2 inhibitor (dapagliflozin or empagliflozin) D. Add vericiguat E. Add hydralazine/isosorbide dinitrate Answer #18 The correct answer is C – Add an SGLT2 inhibitor (dapagliflozin or empagliflozin) For patients with symptomatic HFrEF, neurohormonal antagonists (ACEi, ARB, ARNI; BB; MRA) improve survival and reduce the risk of HF hospitalization. This patient is already on these agents. The addition of an SGLT2 inhibitor on top of neurohormonal blockade reduces the risk of CV death and worsening HF in patients with symptomatic HFrEF and is the next best step for this patient (Class I, LOE A). Vericiguat may be considered in patients with symptomatic HFrEF with HF worsening despite already being on maximally tolerated neurohormonal blockade (Class IIb, LOE B), but first-line therapies should be started first. Hydralazine/Isosorbide dinitrate should be considered in self-identified Black patients or people who have EF ≤ 35% or

Church of Jesus Christ Study Session seeks to generate reflection about areas in the Restored Gospel. Whether it's Come Follow Me, a General Conference talk or a recent Gospel Topic, hopefully you'll find something to keep the Spirit of Christ in your life. Twitter - @mattsroberts90 ldsstudysession@gmail.com You can also join the discussion in the Facebook Group 'Church of Jesus Christ Study Session with Come Follow Me'. You can purchase my book, From Father to Child: Raising a Child to Spiritual Strength in Generation Alpha at the link here: https://www.amazon.co.uk/Father-Child-Spiritual-Strength-Generation-ebook/dp/B08DRLWWZD/ref=mp_s_a_1_3?dchild=1&keywords=from+father+to+child&qid=1596387393&sr=8-3

The following question refers to Section 6.2 of the 2021 ESC CV Prevention Guidelines. The question is asked by Dr. Christian Faaborg-Andersen, answered first by Houston Methodist medicine resident Dr. Najah Khan, and then by expert faculty Dr. Jaideep Patel. Dr. Patel recently graduated from Virginia Commonwealth University cardiology fellowship and is now a preventive cardiologist at the Johns Hopkins Hospital. The CardioNerds Decipher The Guidelines Series for the 2021 ESC CV Prevention Guidelines represents a collaboration with the ACC Prevention of CVD Section, the National Lipid Association, and Preventive Cardiovascular Nurses Association. Question #18 A 60-year-old Black woman with a history of hypertension and heart failure with reduced ejection fraction (EF 40%) presents to clinic for follow-up. She is currently doing well with NYHA class II symptoms. She is taking carvedilol 25 mg BID, sacubitril/valsartan 97/103 mg BID, and spironolactone 25 mg daily, all of which have been well tolerated. In clinic, her BP is 125/80 mmHg, and her HR is 55 bpm. Routine labs are within normal limits including Cr of 1.0, K of 4.0, and HbA1c of 6.0. What is the most appropriate next step in her management? A. No change in management B. Reduce beta blocker C. Add an SGLT2 inhibitor (dapagliflozin or empagliflozin) D. Add vericiguat E. Add hydralazine/isosorbide dinitrate Answer #18 The correct answer is C – Add an SGLT2 inhibitor (dapagliflozin or empagliflozin) For patients with symptomatic HFrEF, neurohormonal antagonists (ACEi, ARB, ARNI; BB; MRA) improve survival and reduce the risk of HF hospitalization. This patient is already on these agents. The addition of an SGLT2 inhibitor on top of neurohormonal blockade reduces the risk of CV death and worsening HF in patients with symptomatic HFrEF and is the next best step for this patient (Class I, LOE A). Vericiguat may be considered in patients with symptomatic HFrEF with HF worsening despite already being on maximally tolerated neurohormonal blockade (Class IIb, LOE B), but first-line therapies should be started first. Hydralazine/Isosorbide dinitrate should be considered in self-identified Black patients or people who have EF ≤ 35% or

How do you like your Obi-Wan? Vader might like him well done.... but we want him alive to continue this great series! Join us as we discuss part 3 and 4 in great depth. Guest host, Adam Lanaghan

This time we read the final story from the first volume of the Grimms' fairy tales: The Fox and the Geese. A tale in which our trusty cunning fox may have taken on more than he bargained for... After the story things get mega foxy as we hear two other stories - that's right, two! - where things don't turn up entirely roses for Reynard: "The Hare And The Fox" by Ludwig Bechstein, and "Beasts In A Pit" collected by Alexander Afanasyev. And that's not all! We also take the time to reintroduce Reynard the Fox (the archetypal trickster fox of Medieval epics), including his incredible connection Disney's Robin Hood. And finally we unveil a new section of the show, "Fox News", where we hear some shocking Kitsune news fresh out of Japan.  Twitter Facebook Instagram Patreon   grimmreadingpodcast@gmail.com Theme music: Bicycle Waltz by Goodbye Kumiko Other Music: Robert Schumann's Scenes from Childhood, Op. 15 - III. Blind Man's Buff // Chopin's Cello Sonata in G Minor, Op. 65 - II. Scherzo // Beethoven's Piano Sonata No.28 in A Major, Op.101 - III & IV.